Pay in 4 interest-free payments of $5.68 Learn more
Ships within 48 hours · Estimated delivery Sep 7 - Sep 12
Commercial insurance : Most major insurers now cover FDA-approved GLP-1 weight-loss medications (Wegovy, Saxenda, Zepbound) with prior authorization
The high-dose version is already approved in the EU in a vial formulation under the Wegovy HD brand name, and is another important line extension for Novo Nordisk as it tries to protect its weight-loss franchise from Lilly's rival injectable Zepbound/Mounjaro (tirzepatide)
Touzot M et al
Hormone replacement therapy (HRT) and contraception are commonly prescribed in primary care, and both are potentially affected by GLP-1 agonists
Tirzepatide: Dual Agonist Therapy Explained Tirzepatide activates both GIP and GLP-1 receptors, two incretin pathways that regulate insulin release, appetite, and metabolic signaling
US$ 20.83
US$ 28.83
US$ 20.46
US$ 26.62
US$ 20.06
